Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study

Immunity & Ageing

Table 1 IL-6 and CRP concentrations in ≥65 year-old seniors

Age (years)	All^a		Successfully aging^b		Others^c
	n	Concentration^d	n	Concentration^d	n	Concentration^d
	IL-6 [pg/mL]
65–69	588	1.8 [1.2, 2.9]	296	1.8 [1.1, 3.0]	292	1.9 [1.3, 2.9]
70–74	681	1.9 [1.3, 3.1]	308	1.7 [1.1, 2.8]	373	2.2 [1.4, 3.3]
75–79	596	2.1 [1.4, 3.4]	231	1.9 [1.3, 2.8]	365	2.4 [1.6, 3.6]
80–84	557	2.5 [1.7, 3.7]	163	2.4 [1.5, 3.5]	394	2.5 [1.7, 3.8]
85–89	598	2.8 [1.8, 4.9]	173	2.7 [1.8, 4.3]	425	2.8 [1.8, 5.1]
90+	476	3.5 [2.1, 5.5]	87	3.3 [2.3, 5.1]	389	3.5 [2.1, 5.6]
	CRP [mg/L]
65–69	614	2.2 [1.1, 4.6]	311	2.0 [1.0, 4.1]	303	2.6 [1.2, 5.5]
70–74	706	2.1 [1.1, 4.1]	321	1.9 [1.0, 3.9]	385	2.2 [1.1, 4.4]
75–79	627	2.2 [1.1, 4.4]	245	1.9 [1.0, 3.8]	382	2.6 [1.2, 4.8]
80–84	572	2.4 [1.1, 5.2]	169	2.4 [1.0, 5.3]	403	2.3 [1.1, 5.2]
85–89	621	2.5 [1.1, 5.1]	177	2.8 [1.2, 4.6]	444	2.4 [1.1, 5.2]
90+	492	2.7 [1.1, 5.5]	89	2.6 [1.3, 5.3]	403	2.7 [1.1, 5.7]

^a: Excluded are individuals with leukocytosis exceeding 10,000/μL or treated with glucocorticoids
^b: Only individuals without past or current cancer, type 2 diabetes, cardiovascular disease/myocardial infarction/stroke, and with the MMSE score ≥24 and the ADL score 5–6
^c: Individuals who did not meet the definition of successful aging
^d: Concentrations of IL–6 and CRP are shown as median [1^st quartile, 3^rd quartile]
n number of individuals

ISSN: 1742-4933